DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $37,524 | +142.9% | 1,616 | +114.6% | 0.00% | – |
| Q1 2024 | $15,451 | +44.3% | 753 | +50.9% | 0.00% | – |
| Q4 2023 | $10,709 | -38.2% | 499 | -40.6% | 0.00% | – |
| Q3 2023 | $17,330 | +0.4% | 840 | +43.6% | 0.00% | – |
| Q2 2023 | $17,263 | +14.2% | 585 | -10.8% | 0.00% | – |
| Q1 2023 | $15,114 | +18.9% | 656 | +43.5% | 0.00% | – |
| Q4 2022 | $12,709 | -15.3% | 457 | -9.1% | 0.00% | – |
| Q3 2022 | $15,000 | +15.4% | 503 | +10.1% | 0.00% | – |
| Q2 2022 | $13,000 | -27.8% | 457 | -18.2% | 0.00% | – |
| Q1 2022 | $18,000 | -10.0% | 559 | +25.9% | 0.00% | – |
| Q4 2021 | $20,000 | -9.1% | 444 | +1.4% | 0.00% | – |
| Q3 2021 | $22,000 | -40.5% | 438 | -8.4% | 0.00% | – |
| Q2 2021 | $37,000 | +37.0% | 478 | +2.6% | 0.00% | – |
| Q1 2021 | $27,000 | -18.2% | 466 | +18.0% | 0.00% | – |
| Q4 2020 | $33,000 | +560.0% | 395 | +180.1% | 0.00% | – |
| Q3 2020 | $5,000 | +150.0% | 141 | +67.9% | 0.00% | – |
| Q2 2020 | $2,000 | – | 84 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
| Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
| Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
| Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
| MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
| Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
| PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
| WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |